These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35597248)

  • 21. Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.
    Hwang H; Kang H; Kwon YS; Jeon D; Shim TS; Yim JJ
    Clin Infect Dis; 2021 Oct; 73(8):1362-1369. PubMed ID: 33837767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling.
    Knight GM; McQuaid CF; Dodd PJ; Houben RMGJ
    Lancet Infect Dis; 2019 Aug; 19(8):903-912. PubMed ID: 31281059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk-benefit analysis of tuberculosis infection testing for household contact management in high-burden countries: a mathematical modelling study.
    Yuen CM; Seddon JA; Keshavjee S; Dodd PJ
    Lancet Glob Health; 2020 May; 8(5):e672-e680. PubMed ID: 32353315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY; Lin CJ
    Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study.
    Ryckman TS; McQuaid CF; Cohen T; Menzies NA; Kendall EA
    Lancet Glob Health; 2024 Oct; 12(10):e1629-e1637. PubMed ID: 39159654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial.
    Fox GJ; Nguyen CB; Nguyen TA; Tran PT; Marais BJ; Graham SM; Nguyen BH; Velen K; Dowdy DW; Mason P; Britton WJ; Behr MA; Benedetti A; Menzies D; Nguyen VN; Marks GB
    BMJ Open; 2020 Jan; 10(1):e033945. PubMed ID: 31900274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.
    Ryckman TS; Schumacher SG; Lienhardt C; Sweeney S; Dowdy DW; Mirzayev F; Kendall EA
    Lancet Glob Health; 2024 Jun; 12(6):e995-e1004. PubMed ID: 38762299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial.
    Rosu L; Madan JJ; Tomeny EM; Muniyandi M; Nidoi J; Girma M; Vilc V; Bindroo P; Dhandhukiya R; Bayissa AK; Meressa D; Narendran G; Solanki R; Bhatnagar AK; Tudor E; Kirenga B; Meredith SK; Nunn AJ; Bronson G; Rusen ID; Squire SB; Worrall E;
    Lancet Glob Health; 2023 Feb; 11(2):e265-e277. PubMed ID: 36565704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of interventions to improve diagnosis and preventive therapy for paediatric tuberculosis in 9 sub-Saharan African countries: A modelling study.
    Mafirakureva N; Mukherjee S; de Souza M; Kelly-Cirino C; Songane MJP; Cohn J; Lemaire JF; Casenghi M; Dodd PJ
    PLoS Med; 2023 Sep; 20(9):e1004285. PubMed ID: 37672524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transmissibility and potential for disease progression of drug resistant
    Becerra MC; Huang CC; Lecca L; Bayona J; Contreras C; Calderon R; Yataco R; Galea J; Zhang Z; Atwood S; Cohen T; Mitnick CD; Farmer P; Murray M
    BMJ; 2019 Oct; 367():l5894. PubMed ID: 31649017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19.
    Tahseen S; Khanzada FM; Rizvi AH; Qadir M; Ghazal A; Baloch AQ; Mustafa T
    PLoS One; 2020; 15(9):e0239328. PubMed ID: 32966321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
    White YN; Solans BP; Denti P; van der Laan LE; Schaaf HS; Vonasek B; Malik AA; Draper HR; Hussain H; Hesseling AC; Garcia-Prats AJ; Savic RM
    Clin Infect Dis; 2024 Mar; 78(3):756-764. PubMed ID: 38340060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of mortality and treatment success of multi-drug resistant and Rifampicin resistant tuberculosis in Zimbabwe: a retrospective cohort analysis of patients initiated on treatment during 2010 to 2015.
    Matambo R; Nyandoro G; Sandy C; Nkomo T; Mutero-Munyati S; Mharakurwa S; Chikaka E; Ngwenya M; Ndongwe G; Pepukai VM
    Pan Afr Med J; 2021; 39():128. PubMed ID: 34527144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
    Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.
    Weerasuriya CK; Harris RC; McQuaid CF; Bozzani F; Ruan Y; Li R; Li T; Rade K; Rao R; Ginsberg AM; Gomez GB; White RG
    BMC Med; 2021 Feb; 19(1):60. PubMed ID: 33632218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
    Ismail NA; Omar SV; Moultrie H; Bhyat Z; Conradie F; Enwerem M; Ferreira H; Hughes J; Joseph L; Kock Y; Letsaolo V; Maartens G; Meintjes G; Ngcamu D; Okozi N; Padanilam X; Reuter A; Romero R; Schaaf S; Te Riele J; Variava E; van der Meulen M; Ismail F; Ndjeka N
    Lancet Infect Dis; 2022 Apr; 22(4):496-506. PubMed ID: 34780706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.
    Dheda K; Chang KC; Guglielmetti L; Furin J; Schaaf HS; Chesov D; Esmail A; Lange C
    Clin Microbiol Infect; 2017 Mar; 23(3):131-140. PubMed ID: 27756712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.
    Shayo GA; Chitama D; Moshiro C; Aboud S; Bakari M; Mugusi F
    BMC Public Health; 2017 Jul; 18(1):35. PubMed ID: 28724374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.